Bukwang Pharmaceutical Co., Ltd.

A003000

KR7003000007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 24/05/2024 am IST			5-day change	1st Jan Change
5,900 ^KRW	-1.67%		-9.92%	-3.28%

14/05	Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01/04	H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.	CI

ImmPACT Bio USA Inc. announced that it has received $18.250003 million in funding from a group of investors

August 18, 2020

On August 18, 2020, ImmPACT Bio USA Inc. closed the transaction. The company amended the terms of the transaction and now received $18,250,002.6657 in the transaction. The transaction included participation from OrbiMed Advisors LLC, Johnson & Johnson Innovation - JJDC, Inc., Takeda Ventures, Inc., RMGP Biopharma Fund, a fund managed by RM Global Partners LLC, Investment Arm, Novartis Venture Funds, Bukwang Pharmaceutical Co., Ltd., Hayan Health Networks and JVC Investment Partners LLC.

The company issued 1,349,463 series A preferred shares at issue price of $13.5239 per share in the transaction.

Latest news about Bukwang Pharmaceutical Co., Ltd.

Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.	01/04	CI
Bukwang Pharmaceutical Shares Surge Following Buyback Program Announcement	26/03	MT
H Delta Private Equity Partnership agreed to acquire 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.	22/03	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
Bukwang Pharmaceutical Co., Ltd.(KOSE:A003000) dropped from KOSPI 200 Index	09/22/09	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	17/22/17	CI
OCI Company Ltd. completed the acquisition of additional 10.878134% stake in Bukwang Pharmaceutical Co., Ltd. (KOSE : A003000) from Kim Sanghun and 8 other shareholders for approximately KRW 150 billion.	03/22/03	CI
OCI Company Ltd. agreed to acquire an additional 10.878134% stake in Bukwang Pharmaceutical Co., Ltd. (KOSE : A003000) from Kim Sanghun and 8 other shareholders for approximately KRW 150 billion.	22/22/22	CI
ImmPACT Bio USA Inc. announced that it has received $110.855843 million in funding from a group of investors	20/22/20	CI
ImmPACT Bio USA Inc. announced that it expects to receive $110.855843 million in funding	14/22/14	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/21/12	CI
ImmPACT Bio USA Inc. announced that it has received $18.250003 million in funding from a group of investors	18/20/18	CI
ImmPACT Bio USA Inc. announced that it expects to receive $20.000009 million in funding	09/20/09	CI
Bukwang Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 8, 2020, has expired.	07/20/07	CI
Bukwang Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 8, 2020, has expired.	07/20/07	CI
Bukwang Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 8, 2020, has expired.	07/20/07	CI
Bukwang Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,916,000 shares.	08/20/08	CI
Bukwang Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	08/20/08	CI

Chart Bukwang Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Bukwang Pharm Co Ltd is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
BUKWANG PHARMACEUTICAL CO., LTD.	-3.28%	296M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.04%	42.95B
OTSUKA HOLDINGS CO., LTD.	+16.92%	21.38B
SANDOZ GROUP AG	+18.33%	15.05B
CIPLA LIMITED	+19.27%	14.45B
ZYDUS LIFESCIENCES LIMITED	+56.12%	13.04B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.73%	6.72B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+11.21%	5.47B